<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03261973</url>
  </required_header>
  <id_info>
    <org_study_id>2017P001544</org_study_id>
    <nct_id>NCT03261973</nct_id>
  </id_info>
  <brief_title>Esophageal Deviation in Atrial Fibrillation Ablation</brief_title>
  <official_title>Esophageal Deviation in Atrial Fibrillation Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Catheter ablation with pulmonary vein (PV) isolation is a commonly performed strategy&#xD;
      employed for the treatment of atrial fibrillation (AF). However, ablation in the posterior&#xD;
      wall of the left atrium can cause thermal injury to the esophagus. Thermal injury is very&#xD;
      common and occurs in up to 40% of AF ablations per some studies. When significant thermal&#xD;
      injury to the esophagus occurs, two significant complications can arise: 1) the formation of&#xD;
      an atrio-esophageal fistula, and 2) gastrointestinal dysmotility. While the occurrence of&#xD;
      fistula is rare, it is a very important complication since it is often fatal. Currently&#xD;
      luminal esophageal temperature monitoring is the most commonly employed modality to prevent&#xD;
      such injury. However, there are limitations to its use, and atrio-esophageal fistulas&#xD;
      continue to be a major problem in AF ablation even when using esophageal temperature&#xD;
      monitoring. Esophageal deviation using either a Transesophageal echocardiogram (TEE) or&#xD;
      Esophagogastroduodenoscopy (EGD) probe has been described in the literature, but the&#xD;
      effectiveness and practicality of these techniques are suboptimal, and have therefore&#xD;
      precluded their use in routine clinical practice. Recently, esophageal deviation using&#xD;
      off-the-shelf equipment (a soft thoracic tube and endotracheal stylet) was tested in the&#xD;
      randomized double-blind multicenter study &quot;Deviating the Esophagus in Atrial Fibrillation&#xD;
      Ablation (DEVIATE-AF)&quot;. In that study the standard practice (i.e., use of luminal esophageal&#xD;
      temperature monitoring) was compared to esophageal deviation using off-the-shelf equipment.&#xD;
      The results were very encouraging showing that esophageal deviation allowed for significant&#xD;
      reductions in esophageal temperature and proportion of premature ablation terminations.&#xD;
      Importantly, esophageal deviation allowed the isolation all PVs in the treatment group, which&#xD;
      was not the case in the control group. One major limitation in the DEVIATE-AF trial was that&#xD;
      off-the-shelf equipment tool was challenging to use. The aim of the Esophageal Deviation in&#xD;
      Atrial Fibrillation Ablation study is to test the feasibility and safety of moving the&#xD;
      esophagus using a specialized esophageal deviation tool (DV8, Manual Surgical Sciences,&#xD;
      Minneapolis, MN).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 17, 2017</start_date>
  <completion_date type="Actual">June 15, 2020</completion_date>
  <primary_completion_date type="Actual">June 15, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With a Minimum Distance of 1 cm Esophageal Deviation Between the Ablation Line for the Ipsilateral Pulmonary Vein (PV) Pairs and the Trailing Edge of the Esophagus.</measure>
    <time_frame>during Atrial Fibrillation (AF) ablation procedure (intraoperative)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With an Average Distance of 2 cm Esophageal Deviation From the Ablation Line for the Ipsilateral PV Pairs.</measure>
    <time_frame>during AF ablation procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Esophageal Laceration</measure>
    <time_frame>within 1-90 days of the procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With PV Reconnection Assessed by Adenosine Infusion</measure>
    <time_frame>during AF ablation procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluoroscopy Time Measured for the Whole Procedure</measure>
    <time_frame>during AF ablation procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure Duration Measured From the Initial Groin Stick to Catheter Removal</measure>
    <time_frame>during the AF ablation procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ablation Time Assessed by the Total Duration of Radiofrequency Energy Delivery</measure>
    <time_frame>during the AF ablation procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>DV8 esophageal deviation tool</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This is a non-randomized one arm study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DV8</intervention_name>
    <description>DV8 esophageal deviation tool</description>
    <arm_group_label>DV8 esophageal deviation tool</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA&#xD;
&#xD;
          -  A maximum of up to 54 patients will be enrolled in this prospective single-center&#xD;
             single-arm study. Patients undergoing AF ablation (including paroxysmal and persistent&#xD;
             AF) will be included in this study. Consistent with the current definitions,&#xD;
             paroxysmal AF are episodes that will self-terminate in less than 24 hours. Persistent&#xD;
             AF, is defined as ≥1 documented AF lasting &gt;1week in duration or lasting less than 7&#xD;
             days but requiring electrical or pharmacological cardioversion to sinus rhythm.&#xD;
&#xD;
          -  Age &gt;18 - Age &lt; 80 yr&#xD;
&#xD;
          -  Documentation of atrial fibrillation (AF)&#xD;
&#xD;
          -  General anesthesia&#xD;
&#xD;
          -  All patients must understand and adhere to the requirements of the study and be&#xD;
             willing to comply with the post study follow-up requirements.&#xD;
&#xD;
        EXCLUSION CRITERIA&#xD;
&#xD;
          -  Any reversible cause of AF (post-surgery, thyroid disorder, etc.)&#xD;
&#xD;
          -  INR (international normalized ratio) &gt; 4.0 at the time of the procedure&#xD;
&#xD;
          -  History of (H/o) of severe esophageal ulcers, strictures, varices, bleeding,&#xD;
             laceration or perforation, esophagitis&#xD;
&#xD;
          -  Severe Gastroesophageal Reflux Disease (GERD)&#xD;
&#xD;
          -  H/o esophageal surgery or any esophageal banding or cautery&#xD;
&#xD;
          -  H/o chest radiation&#xD;
&#xD;
          -  Significant abnormality on Swallowing Impairment Score&#xD;
&#xD;
          -  Mental impairment precluding signing consent or completing follow up&#xD;
&#xD;
          -  Patients with any other significant uncontrolled or unstable medical condition&#xD;
&#xD;
          -  Women who are known to be pregnant or have had a positive β-HCG (Human Chorionic&#xD;
             Gonadotropin) test within 7 days prior to procedure&#xD;
&#xD;
          -  Presence of left atrial thrombus&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 21, 2017</study_first_submitted>
  <study_first_submitted_qc>August 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2017</study_first_posted>
  <results_first_submitted>May 25, 2021</results_first_submitted>
  <results_first_submitted_qc>June 28, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 30, 2021</results_first_posted>
  <last_update_submitted>June 28, 2021</last_update_submitted>
  <last_update_submitted_qc>June 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Moussa C Mansour</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 18, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/73/NCT03261973/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>DV8 Esophageal Deviation Tool</title>
          <description>This is a non-randomized one arm study.&#xD;
Arm: usage of the DV8 esophageal deviation tool during the ablation procedure</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DV8 Esophageal Deviation Tool</title>
          <description>This is a non-randomized one arm study.&#xD;
Arm: usage of the DV8 esophageal deviation tool during the ablation procedure</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.9" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Minimum Distance of 1 cm Esophageal Deviation Between the Ablation Line for the Ipsilateral Pulmonary Vein (PV) Pairs and the Trailing Edge of the Esophagus.</title>
        <time_frame>during Atrial Fibrillation (AF) ablation procedure (intraoperative)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DV8 Esophageal Deviation Tool</title>
            <description>This is a non-randomized one arm study.&#xD;
Arm: usage of the DV8 esophageal deviation tool during the ablation procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Minimum Distance of 1 cm Esophageal Deviation Between the Ablation Line for the Ipsilateral Pulmonary Vein (PV) Pairs and the Trailing Edge of the Esophagus.</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With an Average Distance of 2 cm Esophageal Deviation From the Ablation Line for the Ipsilateral PV Pairs.</title>
        <time_frame>during AF ablation procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DV8 Esophageal Deviation Tool</title>
            <description>This is a non-randomized one arm study.&#xD;
Arm: usage of the DV8 esophageal deviation tool during the ablation procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Average Distance of 2 cm Esophageal Deviation From the Ablation Line for the Ipsilateral PV Pairs.</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced Esophageal Laceration</title>
        <time_frame>within 1-90 days of the procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DV8 Esophageal Deviation Tool</title>
            <description>This is a non-randomized one arm study.&#xD;
Arm: usage of the DV8 esophageal deviation tool during the ablation procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Esophageal Laceration</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With PV Reconnection Assessed by Adenosine Infusion</title>
        <time_frame>during AF ablation procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DV8 Esophageal Deviation Tool</title>
            <description>This is a non-randomized one arm study.&#xD;
Arm: usage of the DV8 esophageal deviation tool during the ablation procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With PV Reconnection Assessed by Adenosine Infusion</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fluoroscopy Time Measured for the Whole Procedure</title>
        <time_frame>during AF ablation procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DV8 Esophageal Deviation Tool</title>
            <description>This is a non-randomized one arm study.&#xD;
Arm: usage of the DV8 esophageal deviation tool during the ablation procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Fluoroscopy Time Measured for the Whole Procedure</title>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.8" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedure Duration Measured From the Initial Groin Stick to Catheter Removal</title>
        <time_frame>during the AF ablation procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DV8 Esophageal Deviation Tool</title>
            <description>This is a non-randomized one arm study.&#xD;
Arm: usage of the DV8 esophageal deviation tool during the ablation procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Procedure Duration Measured From the Initial Groin Stick to Catheter Removal</title>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="212" spread="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ablation Time Assessed by the Total Duration of Radiofrequency Energy Delivery</title>
        <time_frame>during the AF ablation procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DV8 Esophageal Deviation Tool</title>
            <description>This is a non-randomized one arm study.&#xD;
Arm: usage of the DV8 esophageal deviation tool during the ablation procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Ablation Time Assessed by the Total Duration of Radiofrequency Energy Delivery</title>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.2" spread="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The duration of the study was 3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>DV8 Esophageal Deviation Tool</title>
          <description>This is a non-randomized one arm study.&#xD;
Arm: usage of the DV8 esophageal deviation tool during the ablation procedure</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Grace Ha</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-643-1697</phone>
      <email>gha2@mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

